Yarrow Bioscience, Inc. entered into an underwriting agreement on September 10, 2026, to sell 5,769,231 shares of common stock at $26.00 per share. The underwriters exercised their option for an additional 865,384 shares on September 11, 2026. Net proceeds are expected to be approximately $161.8 million after deducting discounts and offering expenses. The offering closed on September 14, 2026, with directors and executives subject to a 60-day lock-up period. Yarrow Bioscience operates in the biotechnology industry, focusing on drug discovery and development.

Yarrow Bioscience, Inc. entered into an exchange agreement with an existing stockholder to swap 133,290 shares of common stock for pre-funded warrants to purchase the same number of shares at $0.0001 per share. The transaction closed on July 29, 2026, resulting in 2,669,788 outstanding shares and 25,914,530 outstanding pre-funded warrants. This corporate action is not material to investors as it involves a routine exchange with no change in control or significant capital raise. The company operates in the biotechnology industry.

Yarrow Bioscience, Inc. (formerly VYNE Therapeutics) completed its merger with Pre-Merger Yarrow on July 27, 2026, resulting in a combined entity valued at approximately $281.4 million. Pre-Merger Yarrow stockholders received 0.7171 shares of combined company common stock for each share held, owning approximately 97% of the new company, while VYNE stockholders retained approximately 3%. The transaction was supported by $200 million in pre-closing private financings. Prior to the merger, VYNE effected a 1-for-50 reverse stock split effective July 24, 2026, and distributed a special cash dividend of $0.40242 per share to its stockholders. The combined company, now trading under ticker YARW, appointed a new leadership team including CEO Rebecca Frey and a six-member board. Yarrow Bioscience, Inc. is a clinical-stage biotechnology company focused on developing therapies for autoimmune thyroid diseases.

VYNE Therapeutics announced a 1-for-50 reverse stock split and a special cash dividend of approximately $0.40242 per share, totaling $17.3 million, in connection with its proposed merger with Yarrow Bioscience. The reverse stock split is expected to reduce outstanding shares from 33.4 million to 0.7 million, and the combined company will trade as Yarrow Bioscience, Inc. under the ticker YARW starting July 27, 2026. Stockholders also approved increasing authorized common stock from 150 million to 300 million shares. VYNE is a clinical-stage biopharmaceutical company developing therapies for inflammatory and immune-mediated conditions.

VYNE Therapeutics Inc. held a special meeting on July 16, 2026, where stockholders approved several key proposals related to its merger with Yarrow Bioscience, Inc. Approved measures include the issuance of VYNE common stock to Yarrow stockholders, an amendment to the charter to increase authorized shares from 150,000,000 to 300,000,000, and a reverse stock split with a ratio between 1-for-10 and 1-for-70. Additionally, stockholders approved the Yarrow Bioscience 2026 Stock Incentive Plan, the 2026 Employee Stock Purchase Plan, the election of Sharon Barbari to the board, the ratification of Baker Tilly US, LLP as independent auditors, and advisory votes on executive compensation. VYNE Therapeutics Inc. is a biotechnology company.

VYNE Therapeutics Inc. published an investor presentation on July 14, 2026, regarding a proposed transaction between VYNE and Yarrow Bioscience, Inc. The presentation is intended for investor relations and is accompanied by an attached Exhibit 99.1. VYNE Therapeutics Inc. operates in the biotechnology/pharmaceutical industry and develops therapeutic solutions for various medical conditions.